Scarica l'app Stockscreener
36.70
5.92%
2.05
Precedente Chiudi:
$34.65
Aprire:
$35.13
Volume 24 ore:
625.62K
Relative Volume:
0.71
Capitalizzazione di mercato:
$1.69B
Reddito:
-
Utile/perdita netta:
$-146.66M
Rapporto P/E:
-13.33
EPS:
-2.7541
Flusso di cassa netto:
$-133.21M
1 W Prestazione:
-4.25%
1M Prestazione:
-3.78%
6M Prestazione:
+3.38%
1 anno Prestazione:
-17.45%
Intervallo 1D:
$34.58
$37.08
Intervallo di 1 settimana:
$34.34
$38.33
Portata 52W:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Confronta APGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
36.70 | 2.02B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Reiterato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Apogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory Challenges - MSN
Apogee Therapeutics Reports Promising Trial Results and Strong Cash Position - TipRanks
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Apogee Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Apogee Therapeutics Q2 2025: A Catalyst-Driven Path to Re-Rating - AInvest
Apogee Therapeutics stock holds steady as Goldman Sachs reiterates rating - Investing.com
Apogee Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Apogee Therapeutics provides pipeline progress and reports second quarter 2025 financial results - MarketScreener
Apogee Therapeutics Provides Pipeline Progress And Reports Second Quarter 2025 Financial Results - TradingView
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics Q2 Net Loss Widens - MarketScreener
Apogee Therapeutics Q2 2025 Financial Results and Pipeline Progress - TradingView
Breakthrough: Apogee's New Atopic Dermatitis Drug Achieves 71% Efficacy with 6-Month Dosing Potential - Stock Titan
Apogee Therapeutics APGE Q2 2025 Earnings Preview Upside Potential Hinges on Strategic Partnerships - AInvest
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - 富途牛牛
Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - Yahoo Finance
What are the latest earnings results for Apogee Therapeutics Inc.Outstanding capital returns - Jammu Links News
When is Apogee Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
Is Apogee Therapeutics Inc. a growth stock or a value stockFastest-growing stock picks - Jammu Links News
What is the risk reward ratio of investing in Apogee Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
How many analysts rate Apogee Therapeutics Inc. as a “Buy”Maximize your returns with expert insights - Jammu Links News
Is Apogee Therapeutics Inc. a good long term investmentInvest smarter with expert stock picks - Jammu Links News
Should I hold or sell Apogee Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Is it the right time to buy Apogee Therapeutics Inc. stockAchieve consistent double-digit growth rates - Jammu Links News
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
How volatile is Apogee Therapeutics Inc. stock compared to the marketChart Pattern Updates For Fast Growth - Jammu Links News
What’s next for Apogee Therapeutics Inc. stock priceTop Performing Stock Insights Released Daily - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Published on: 2025-07-30 23:15:33 - metal.it
Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma - MSN
Earnings visualization tools for Apogee Therapeutics Inc.Earnings Impact and Stock Reaction Analysis - Newser
Multi Factor Analysis Ranks Apogee Therapeutics Inc. as Strong BuyIntraday Trend Analysis for Fast Gains Released - metal.it
Order Book Volume Tilts Bullish on Apogee Therapeutics Inc.Trade Ready Stock Watch for Short Term Published - metal.it
Is Apogee Therapeutics Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
What makes Apogee Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Intrinsic Value of Apogee Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree Elite Traders Group - Newser
What analysts say about Apogee Therapeutics Inc. stockOver 200% growth - PrintWeekIndia
What drives Apogee Therapeutics Inc. stock priceDynamic growth stocks - Autocar Professional
Apogee Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - Autocar Professional
What makes Apogee Therapeutics Inc. stock attractive to long term investorsDynamic growth stocks - Jammu Links News
InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics By Investing.com - Investing.com Canada
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):